News Center
NEWS CENTER

Shangke Bio has been awarded the “Rising Star in Synthetic Biology” prize.


Classification: Company News

Publication:2023-10-20 18:33

On October 19, 2023, the “2023 Shanghai International Biopharmaceutical Industry Week Synthetic Biology Technology Innovation Industry Conference,” co-hosted by Lingang Group and Dandelion, was held at Shanghai Lingang Life Bay. SyncoZymes (Shanghai) Co., Ltd. was awarded the “2023 Rising Star in Synthetic Biology” prize, and the company’s general manager also delivered a roadshow at the event, introducing SyncoZymes’ profile to the attendees.
On October 19, 2023, the “2023 Shanghai International Biopharmaceutical Industry Week Synthetic Biology Technology Innovation Industry Conference,” co-hosted by Lingang Group and Dandelion, was held at Shanghai Lingang Life Science Bay. SyncoZymes (Shanghai) Co., Ltd. was awarded the “2023 Rising Star in Synthetic Biology” prize, and the company’s general manager also delivered a pitch at the event, presenting SyncoZymes’ profile to the attendees.

(Image | Award Ceremony for Emerging Synthetic Biology Companies)
At the heart of synthetic biology companies is the application of the engineering DBTL cycle—design, build, test, and learn—to the life sciences, thereby overcoming relevant production bottlenecks. It uses biomacromolecules such as DNA, RNA, and proteins as foundational components, and through approaches including discovery, research, synthesis, engineering, expression, and application, either directly produces target products—such as high-value-added compounds, disease therapies, or improved crops—or establishes diverse toolkits and databases, including enzyme libraries, strain collections, and omics repositories, thereby providing services to both upstream and downstream stakeholders.

This selection process primarily… The selection process evaluates companies across multiple dimensions, including their innovation achievements, core technologies, and financing status. The organizing committee has invited leading industry experts to provide guidance and recommendations. The selection of the “2023 Rising Stars in Synthetic Biology” list has been finalized.

          Image

(Image | Trophy for Emerging Synthetic Biology Companies)

At this conference, Shangke Bio was honored with the title of “2023 Rising Star in Synthetic Biology,” a testament to the company’s strong innovation capabilities and significant growth potential. The company will remain committed to research and investment in cutting-edge green pharmaceutical technologies and products, leveraging green biotechnology to drive the development of the chemical pharmaceutical industry, and striving tirelessly to deliver high‑quality products and exceptional services to the pharmaceutical sector.

 

 

About Shangke Bio

SyncoZymes (Shanghai) Co., Ltd. was founded in late 2007 and has now become a closed-loop industrial-chain enterprise integrating R&D in biocatalysis and synthetic biology, production of pharmaceutical intermediates and APIs, and manufacturing of drug formulations. Leveraging four core technology platforms, SyncoZymes has built an enzyme library encompassing more than 50 enzyme systems, as well as a comprehensive range of coenzyme products—including NMN, NAD, NADP, NADH, NADPH, FMN, FAD, PAPS, and others. The Group’s principal business lines include: the development and application of bioenzymes; the research, production, and sales of pharmaceutical intermediates, APIs, functional chemicals, and drug formulations; and CRO/CDMO services for bioenzymes, pharmaceutical intermediates, APIs, and drug formulations.

 
 
 
 
 
 
 
 
 
 
 
 
 

 


Leave a Message Online

yzm
Submit